AstraZeneca has submitted an NDA to the FDA for vandetanib 100 mg for use in combination with chemotherapy for the treatment of advanced non-small cell lung cancer in patients previously treated with one prior anti-cancer therapy. The company also submitted an MAA to the EMEA for the drug. If approved, the treatment will be marketed as Zactima. Evaluation of vandetanib is ongoing as a monotherapy or in combination with other anti-cancer therapies in a range of tumor types, including thyroid c...